Webinar Overview:
Artificial intelligence (AI) has seen expansive growth and breakthroughs in mental health and substance use disorder care in recent years. This wave of innovation is becoming increasingly entrenched in health care and making an impact on the lives of people with behavioral health conditions.
In this webinar, we will:
• Understand how and where AI is being used in behavioral health and its possibilities for the future
• Discover the approach the U.S. Food and Drug Administration takes with AI including how AI is defined, the types of products already approved, and the pathways these products went through prior to approval
• Learn how one health plan is using AI for behavioral health integration and the components critical to its success
• Sergio de del Castillo, Associate Director for Policy at the Office of Health Technology at the U.S. Food and Drug Administration (FDA)
• Bernard DiCasimirro, Chief Medical Officer at Lucet
• Jodi Daniel, Partner & CHS Managing Director at Crowell & Moring
